Compare BA & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BA | NVS |
|---|---|---|
| Founded | 1916 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | 75267 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2B | 286.5B |
| IPO Year | 2005 | N/A |
| Metric | BA | NVS |
|---|---|---|
| Price | $214.23 | $149.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 5 |
| Target Price | ★ $269.75 | $144.00 |
| AVG Volume (30 Days) | ★ 6.5M | 1.5M |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 2.16% |
| EPS Growth | ★ 113.51 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $89,463,000,000.00 | N/A |
| Revenue This Year | $12.16 | $2.30 |
| Revenue Next Year | $14.78 | $5.27 |
| P/E Ratio | ★ N/A | $23.13 |
| Revenue Growth | ★ 34.50 | N/A |
| 52 Week Low | $176.77 | $112.34 |
| 52 Week High | $254.35 | $170.46 |
| Indicator | BA | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 51.47 |
| Support Level | $212.87 | $145.30 |
| Resistance Level | $228.02 | $152.55 |
| Average True Range (ATR) | 6.20 | 2.02 |
| MACD | -1.18 | -0.08 |
| Stochastic Oscillator | 20.38 | 67.48 |
Boeing is a major aerospace and defense firm operating in three segments: commercial airplanes; defense, space, and security; and global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with defense contractors such as Lockheed Martin and Northrop Grumman to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.